Compugen (CGEN)
Compugen Earnings Per Share Growth
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
About EPS Growth
YCharts EPS growth rates are calculated as quarterly year on year growth rates.
EPS growth (earnings per share growth) illustrates the growth of earnings per share over time. EPS growth rates help investors identify stocks that are increasing or decreasing in profitability.
If a company has an EPS of $5.00 in 2008 and EPS of $6.00 in 2009, the company has an EPS growth rate of $6.00/$5.00 - 1 = 20% during fiscal year 2009.
Learn More
You may also be interested in these CGEN related companies
CGEN News
Compugen First Quarter 2012 Conference Call Scheduled for Tuesday, May 1, 2012 at 10:00 AM EST
Apr 23, 7:00AM Business Wire
Apr 23, 7:00AM Business Wire
$CGEN has been consolidating for a long time. Seems to be a lot of green in it like my face.
about 53 days ago by Mr_Yuck
about 53 days ago by Mr_Yuck
Compugen Establishes Operations in California for Development of Monoclonal Antibody Drug Candidates
Mar 28, 7:00AM Business Wire
Mar 28, 7:00AM Business Wire
$CGEN http://stks.co/35sm volume laden impulse over $6 would be clear trigger
about 62 days ago by traderdigs
about 62 days ago by traderdigs
Compugen Presents Prediction Based Discovery Strategy at “Targets and Strategies for Drug Discovery” Conference
Feb 27, 7:04AM Business Wire
Feb 27, 7:04AM Business Wire
Compugen Ltd. Reports Fourth Quarter and Calendar 2011 Financial Results
Feb 07, 7:00AM Business Wire
Feb 07, 7:00AM Business Wire
Compugen (CGEN) Updates on CGEN-15001T Therapeutic Potential as Cancer Treatment
Feb 02, 7:29AM Street Insider
Feb 02, 7:29AM Street Insider
Compugen Says Cancer Target Results Demonstrate Significant Potential for Cancer Immunotherapy
Feb 02, 6:42AM Benzinga
Feb 02, 6:42AM Benzinga
Compugen Cancer Target Results Demonstrate Significant Potential for Cancer Immunotherapy
Feb 02, 6:00AM Business Wire
Feb 02, 6:00AM Business Wire
Compugen Fourth Quarter 2011 Conference Call Scheduled for Tuesday, February 7, 2012 at 10:00 AM EST
Jan 31, 8:56AM Business Wire
Jan 31, 8:56AM Business Wire
Compugen to Broaden and Accelerate Monoclonal Antibody Program for Oncology and Immunology
Dec 20, 10:30AM Business Wire
Dec 20, 10:30AM Business Wire
Compugen presents predictive drug target discovery platform at Euro conference
Nov 30, 7:02AM FlyOnTheWall
Nov 30, 7:02AM FlyOnTheWall
Compugen Presents Predictive Drug Target Discovery Platform at European Antibody Conference
Nov 30, 7:00AM Business Wire
Nov 30, 7:00AM Business Wire
Compugen and DiscoveRx® Form Collaboration to Commercialize Novel Peptide Ligands for GPCR Drug Targets
Nov 29, 7:00AM Business Wire
Nov 29, 7:00AM Business Wire
Compugen's CGEN-15001 Pre-Clinical Data Presented at International Conference on Immune Tolerance
Oct 25, 7:00AM Business Wire
Oct 25, 7:00AM Business Wire
Compugen Third Quarter 2011 Conference Call Scheduled for Tuesday, November 8, 2011 at 10:00 AM EST
Oct 24, 7:00AM Business Wire
Oct 24, 7:00AM Business Wire
Pulmonary Fibrosis Foundation to Fund Further Therapeutic Evaluation Studies for Compugen-Discovered Drug Candidate
Oct 12, 8:00AM Business Wire
Oct 12, 8:00AM Business Wire
$CGEN http://stks.co/KoY ugly candle but closed over a support on low volume pullback so potential long
about 249 days ago by StockTiger
about 249 days ago by StockTiger
Compugen announces validation of two immune system modulating drug candidates
Sep 13, 7:04AM FlyOnTheWall
Sep 13, 7:04AM FlyOnTheWall
Compugen Second Quarter 2011 Conference Call Scheduled for Tuesday, August 2, 2011 at 10:00 AM EDT
Jul 27, 7:01AM Business Wire
Jul 27, 7:01AM Business Wire
Compugen Announces Initial Validation of Additional B7/CD28 Protein Family Based Product Candidate
Jun 21, 8:06AM Business Wire
Jun 21, 8:06AM Business Wire
Compugen Discloses Discovery Method for Drug Candidates That Interfere With Protein Conformations
May 19, 7:00AM Business Wire
May 19, 7:00AM Business Wire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CGEN | 3.80 | -0.25 | -6.17% | 131.90M |
| CEDU | 6.88 | +0.00 | +0.00% | 126.66M |
| CEDC | 4.04 | +0.02 | +0.50% | 295.49M |
| CECO | 7.03 | +0.72 | +11.41% | 474.81M |
| CECE | 7.15 | +0.11 | +1.56% | 103.82M |
| CEC | 35.78 | -0.22 | -0.61% | 646.90M |
| CEBK | 30.50 | +0.00 | +0.00% | 51.24M |
| CEA | 14.45 | -0.10 | -0.69% | 2.769B |
| COGO | 1.89 | +0.02 | +1.07% | |
| COG | 34.77 | -0.30 | -0.86% | 7.282B |